| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8734231 | Pediatric Hematology Oncology Journal | 2018 | 14 Pages |
Abstract
Bio-similar PEG-ASP in combination with chemotherapy is safe and well tolerated in Indian patients with ALL. No new safety signal was generated in this analysis. Adverse events reported were similar to those seen with innovator in the global published data.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Anil Kamat,